Novo Nordisk A/S (NYSE:NVO) shares gapped up prior to trading on Thursday after the company announced a dividend. The stock had previously closed at $45.21, but opened at $44.57. Novo Nordisk A/S shares last traded at $44.06, with a volume of 1,202,701 shares traded.

The newly announced dividend which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be paid a dividend of $0.336 per share. The ex-dividend date of this dividend is Friday, August 18th. This is a positive change from Novo Nordisk A/S’s previous dividend of $0.33. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 35.84%.

A number of equities analysts have weighed in on the company. BidaskClub lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.00.

The firm has a market capitalization of $110.11 billion, a PE ratio of 18.1490 and a beta of 0.63. The firm’s 50-day moving average is $42.68 and its 200 day moving average is $38.69.

A number of large investors have recently made changes to their positions in NVO. Alta Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 11.1% in the first quarter. Alta Capital Management LLC now owns 922,362 shares of the company’s stock worth $31,618,000 after buying an additional 92,509 shares during the last quarter. Reliance Trust Co. of Delaware boosted its position in shares of Novo Nordisk A/S by 42.3% in the first quarter. Reliance Trust Co. of Delaware now owns 22,977 shares of the company’s stock worth $788,000 after buying an additional 6,829 shares during the period. Howland Capital Management LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $266,000. Cim LLC boosted its position in shares of Novo Nordisk A/S by 0.5% in the first quarter. Cim LLC now owns 196,121 shares of the company’s stock worth $6,723,000 after buying an additional 1,045 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $449,000. Hedge funds and other institutional investors own 6.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Novo Nordisk A/S (NVO) Shares Gap Up After Dividend Announcement” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/novo-nordisk-as-nvo-shares-gap-up-after-dividend-announcement/1470433.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.